Share on StockTwits

ZS Pharma (NASDAQ:ZSPH) posted its quarterly earnings results on Thursday. The company reported ($4.72) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.66) by $4.06, AR Network reports.

ZSPH has been the subject of a number of recent research reports. Analysts at Credit Suisse initiated coverage on shares of ZS Pharma in a research note on Monday, July 14th. They set an “outperform” rating and a $51.00 price target on the stock. On the ratings front, analysts at William Blair initiated coverage on shares of ZS Pharma in a research note on Monday, July 14th. They set an “outperform” rating and a $75.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. initiated coverage on shares of ZS Pharma in a research note on Monday, July 14th. They set an “overweight” rating and a $43.00 price target on the stock.

ZS Pharma (NASDAQ:ZSPH) traded down 2.45% during mid-day trading on Thursday, hitting $29.02. The stock had a trading volume of 29,469 shares. ZS Pharma has a 52-week low of $25.51 and a 52-week high of $33.00. The stock has a 50-day moving average of $28.74 and a 200-day moving average of $28.71. The company’s market cap is $572.2 million.

ZS Pharma, Inc is a biopharmaceutical company focused on the development and commercialization of selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.